Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML, Almeida J, Vidriales B, López-Berges MC, García-Marcos MA, Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A. Sánchez ML, et al. Among authors: calmuntia mj. Leukemia. 2002 Aug;16(8):1460-9. doi: 10.1038/sj.leu.2402584. Leukemia. 2002. PMID: 12145686
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
Vidriales MB, Pérez JJ, López-Berges MC, Gutiérrez N, Ciudad J, Lucio P, Vazquez L, García-Sanz R, del Cañizo MC, Fernández-Calvo J, Ramos F, Rodríguez MJ, Calmuntia MJ, Porwith A, Orfao A, San-Miguel JF. Vidriales MB, et al. Among authors: calmuntia mj. Blood. 2003 Jun 15;101(12):4695-700. doi: 10.1182/blood-2002-08-2613. Epub 2003 Feb 13. Blood. 2003. PMID: 12586618 Free article.
An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia.
Martínez A, San Miguel JF, Vidriales MB, Ciudad J, Caballero MD, López-Berges MC, Moro MJ, Calmuntia MJ, Ortega F, Orfao A. Martínez A, et al. Among authors: calmuntia mj. Cytometry. 1999 Apr 15;38(2):70-5. doi: 10.1002/(sici)1097-0320(19990415)38:2<70::aid-cyto4>3.0.co;2-s. Cytometry. 1999. PMID: 10323219 Free article. Clinical Trial.
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.
San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C, Ramos F, Calmuntia MJ, Pérez JJ, González M, Orfao A. San Miguel JF, et al. Among authors: calmuntia mj. Blood. 2001 Sep 15;98(6):1746-51. doi: 10.1182/blood.v98.6.1746. Blood. 2001. PMID: 11535507 Free article.
Bone remodelation markers are useful in the management of monoclonal gammopathies.
Hernández JM, Suquía B, Queizan JA, Fisac RM, Sanchez JJ, Fernández-Calvo FJ, García-Sanz R, Olivier C, Bárez A, Calmuntia MJ, García-Frade J, Portero JA, López R, Aguilera C, Navajo JA, San-Miguel JF. Hernández JM, et al. Among authors: calmuntia mj. Hematol J. 2004;5(6):480-8. doi: 10.1038/sj.thj.6200564. Hematol J. 2004. PMID: 15570289 Clinical Trial.
[Incidence of haematological neoplasms in Castilla y León, Spain].
Rodríguez-García JA, Vázquez L, Ramos F, Cuevas B, Martín A, Smucler A, Guerola DN, Cantalapiedra A, Alonso JM, Fernández S, Díez E, Rodríguez MJ, Calmuntia MJ, Aguilar C, Sierra M, Gracia JA, Cebeira MJ, Cantalejo R; en nombre del Grupo de trabajo del Registro de Enfermedades Hematológicas de Castilla y León, Sociedad Castellano-Leonesa de Hematología y Hemoterapia. Rodríguez-García JA, et al. Among authors: calmuntia mj. Med Clin (Barc). 2015 Jun 8;144(11):491-500. doi: 10.1016/j.medcli.2014.03.037. Epub 2014 Jul 9. Med Clin (Barc). 2015. PMID: 25015251 Spanish.
14 results